MOLECULAR PARTNERS (Switzerland) Today

Equity ratings for MOLECULAR PARTNERS N are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of August 2019 and ending today, the 30th of July 2021. Click here to learn more.
MOLECULAR PARTNERS N cannot be verified against its exchange. Apparently, MOLECULAR PARTNERS is not available for investing at the moment. Please verify the symbol is currently traded on Switzerland Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

MOLECULAR PARTNERS Stock Profile

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 117 people.. The public information regarding MOLECULAR PARTNERS N's current market price is not available at this time.
MOLECULAR PARTNERS is not yet fully synchronised with the market data
MOLECULAR PARTNERS has some characteristics of a very speculative penny stock
MOLECULAR PARTNERS has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 10.36 M. Net Loss for the year was (37.04 M) with loss before overhead, payroll, taxes, and interest of (27.85 M).
MOLECULAR PARTNERS N has accumulated about 98.96 M in cash with (42.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.66.
Legal NameMOLECULAR PARTNERS N
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of MOLECULAR PARTNERS's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
MOLECULAR PARTNERS N (MOLN) is traded on Switzerland Exchange in Switzerland and employs 117 people. The company currently falls under 'Small-Cap' category with current market capitalization of 281.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MOLECULAR PARTNERS's market, we take the total number of its shares issued and multiply it by MOLECULAR PARTNERS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. MOLECULAR PARTNERS operates under Healthcare sector and is part of Biotechnology industry. The entity has 20.72 M outstanding shares. MOLECULAR PARTNERS N has accumulated about 98.96 M in cash with (42.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.66.
Check MOLECULAR PARTNERS Probability Of Bankruptcy

MOLECULAR Stock Against Markets

Picking the right benchmark for MOLECULAR PARTNERS stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in MOLECULAR PARTNERS stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for MOLECULAR PARTNERS is critical whether you are bullish or bearish towards MOLECULAR PARTNERS N at a given time.
MOLECULAR PARTNERS N cannot be verified against its exchange. Apparently, MOLECULAR PARTNERS is not available for investing at the moment. Please verify the symbol is currently traded on Switzerland Exchange. If you still believe the symbol you are trying to look up is valid please let us know and we will check it as soon as possible.
Refresh

Try Other Stock Suggestions

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MOLECULAR PARTNERS stock to make a market-neutral strategy. Peer analysis of MOLECULAR PARTNERS could also be used in its relative valuation, which is a method of valuing MOLECULAR PARTNERS by comparing valuation metrics with similar companies.
Check out Stocks Correlation. Note that the MOLECULAR PARTNERS information on this page should be used as a complementary analysis to other MOLECULAR PARTNERS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Tools for MOLECULAR Stock

When running MOLECULAR PARTNERS price analysis, check to measure MOLECULAR PARTNERS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MOLECULAR PARTNERS is operating at the current time. Most of MOLECULAR PARTNERS's value examination focuses on studying past and present price action to predict the probability of MOLECULAR PARTNERS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move MOLECULAR PARTNERS's price. Additionally, you may evaluate how the addition of MOLECULAR PARTNERS to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go